It is called a targeted therapy because it particularly targets the CD38 which can be overexpressed about the multiple myeloma cells. Daratumumab is from a class of medicines known as CD38 monoclonal antibodies. They are biological products and solutions that have presently been approved via the FDA, against which biosimilar https://adhdozempic.com/